SCHEMBL7560969

SCHEMBL7560969

Cc1cc(C)c(-n2c3ccccc3c3c(Cl)nc(C)nc32)c(C)c1

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 11/20 0.59
TDP1 Q9NUW8 2/20 0.37
DPP4 P27487 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2A6 P11509 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7555469 0.85 CRHR1 (0.58) CRHR1TDP1DPP4CYP1A2CYP2A6
SCHEMBL7684798 0.84 CRHR1 (0.51) CRHR1DPP4CYP1A2CYP2A6
SCHEMBL7788894 0.78 CRHR1 (0.62) CRHR1TDP1
SCHEMBL7681407 0.78 CRHR1 (0.54) CRHR1TDP1CYP1A2
SCHEMBL226802 0.78 CRHR1 (0.77) CRHR1TDP1
SCHEMBL7682689 0.78 CRHR1 (0.51) CRHR1CYP1A2
SCHEMBL7677531 0.77 CRHR1 (0.53) CRHR1TDP1DPP4CYP1A2CYP2A6
SCHEMBL6092339 0.77 CRHR1 (0.57) CRHR1TDP1
SCHEMBL7557048 0.77 CRHR1 (0.52) CRHR1
SCHEMBL7788887 0.77 CRHR1 (0.55) CRHR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6362186-B1 PSYCHOLOGICAL DISORDERS NEUROGEN CORPORATION 2002-03-26 US disclosed
US-20020019406-A1 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands NEUROGEN CORPORATION 2002-02-14 US disclosed
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NEUROGEN CORPORATION 2001-10-18 US disclosed
US-6284766-B1 DIAGNOSIS, THERAPY OF STRESS DISORDERS NEUROGEN CORPORATION 2001-09-04 US disclosed
US-6221875-B1 TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL NEUROGEN CORPORATION 2001-04-24 US disclosed
US-6147085-A Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives NEUROGEN CORPORATION (US) 2000-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019406-A1 9H-pyrimido[4,5-b]indole derivatives: CRF1 specific ligands HTR1D, CRHR1, HTR1A CRHR1 2/4885TDP1 2969/4885DPP4 1652/4885
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NPY1R, NPY2R, NPY5R CRHR1 33/4885TDP1 2365/4885DPP4 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.